Advertisement |
|
Harrington Discovery Institute at University Hospitals in Cleveland, Ohio — part of The Harrington Project for Discovery & Development — announces the 2016 Harrington Scholar-Innovator Award, a search for physician-scientists seeking to advance promising discoveries into patient treatments. Letters of Intent accepted through May 1, 2015. Apply at HarringtonDiscovery.org. | | | |
|
|
TABLE OF CONTENTS
|
March 2015 Volume 21, Issue 3 |
| | |
| Editorial News Correspondence News and Views Between Bedside and Bench Review Articles Letters Technical Report | |
|
|
|
|
Advertisement |
|
The Biology of Regenerative Medicines (22-24 April 2015) Wellcome Trust Genome Campus, Hinxton, Cambridge, UK Join developmental-, regenerative- and stem cell biologists to discuss the biology of regeneration and how stem cells and the regenerative process can be exploited to treat disease. Abstract Deadline: 2 Mar. Registration Deadline: 20 Mar. | | | |
|
|
Advertisement |
|
Chronic Lymphocytic Leukemia: Recent advances in biology and therapy Access this new Collection from Leukemia available free online. Produced with support from: Janssen Pharmaceuticals Companies of Johnson & Johnson | | | |
|
|
Editorial | Top |
|
|
|
A double-blind option for peer review p199 doi:10.1038/nm.3817 Together with Nature and the other Nature-branded monthly journals, Nature Medicine is offering authors the option to remain anonymous during the peer-review process. |
|
News | Top |
|
|
|
Threat of interim data leaks prompts call for international rules p200 Mollie Bloudoff-Indelicato doi:10.1038/nm0315-200 |
|
|
|
New technologies take root in the search for antibiotics from soil p201 Jop de Vrieze doi:10.1038/nm0315-201 |
|
|
|
News in Brief |
|
|
|
Biomedical briefing pp202 - 203 doi:10.1038/nm0315-202 |
|
|
|
Insurance companies are slow to cover next-generation sequencing pp204 - 205 Shraddha Chakradhar doi:10.1038/nm0315-204 |
|
|
|
Copy number variations' effect on drug response still overlooked p206 Cassandra Willyard doi:10.1038/nm0315-206 |
|
|
|
Natural killers: Cataloging immune cells for immunotherapy pp207 - 208 Amanda B. Keener doi:10.1038/nm0315-207 |
|
|
|
Training on trials: Patients taught the language of drug development pp209 - 210 Shraddha Chakradhar doi:10.1038/nm0315-209 |
|
Correspondence | Top |
|
|
|
Timing is everything for compassionate use of delamanid p211 Clifton E Barry III doi:10.1038/nm.3823 |
|
News and Views | Top |
|
|
|
|
|
Between Bedside and Bench | Top |
|
|
|
Understanding Biomarkers of Neurodegeneration: Ultrasensitive detection techniques pave the way for mechanistic understanding pp217 - 219 Kaj Blennow and Henrik Zetterberg doi:10.1038/nm.3810 New methods for detecting indications of neurodegeneration are necessary to diagnose neurodegenerative diseases. In identifying suitable biomarkers that can be monitored by these techniques, the pathogenic mechanisms that lead to these diseases may also be elucidated. |
|
|
|
Understanding Biomarkers of Neurodegeneration: Novel approaches to detecting tau pathology pp219 - 220 Casey N Cook, Melissa E Murray and Leonard Petrucelli doi:10.1038/nm.3809 Tau pathology is commonly analyzed by positron emission tomography (PET) imaging. However, recently developed cell-based techniques for analyzing tau pathogenicity may also be used to measure an early biomarker in tauopathies. |
|
Review | Top |
|
|
|
Anemia: progress in molecular mechanisms and therapies pp221 - 230 Vijay G Sankaran and Mitchell J Weiss doi:10.1038/nm.3814 The progress in understanding the mechanistic causes of anemias such as hemoglobinopathies and rare genetic disorders, as well as advances in therapies for anemias are reviewed. |
|
Articles | Top |
|
|
|
Synthetic lethality by targeting EZH2 methyltransferase activity in ARID1A-mutated cancers pp231 - 238 Benjamin G Bitler, Katherine M Aird, Azat Garipov, Hua Li, Michael Amatangelo et al. doi:10.1038/nm.3799 Ovarian tumors with common mutations in the epigenetic regulator ARID1A are shown to be sensitive to inhibition of EZH2, another epigenetic regulator, showing a synthetic lethality that could potentially be exploited therapeutically |
|
|
|
LTB4 promotes insulin resistance in obese mice by acting on macrophages, hepatocytes and myocytes pp239 - 247 Pingping Li, Da Young Oh, Gautam Bandyopadhyay, William S Lagakos, Saswata Talukdar et al. doi:10.1038/nm.3800 Genetic and pharmacological inhibition of the high-affinity LTB4 receptor promotes improved metabolism in obese mice. |
|
|
|
A small-molecule inhibitor of the NLRP3 inflammasome for the treatment of inflammatory diseases pp248 - 255 Rebecca C Coll, Avril A B Robertson, Jae Jin Chae, Sarah C Higgins, Raul Munoz-Planillo et al. doi:10.1038/nm.3806 A selective, small-molecule inhibitor of NLRP3 suppresses activation of the inflammasome in vitro and in vivo and attenuates inflammatory disease. See also: News and Views by Levy et al. | Letter by Youm et al. |
|
Letters | Top |
|
|
|
Modeling colorectal cancer using CRISPR-Cas9-mediated engineering of human intestinal organoids pp256 - 262 Mami Matano, Shoichi Date, Mariko Shimokawa, Ai Takano, Masayuki Fujii et al. doi:10.1038/nm.3802 Genome editing applied to human intestinal organoids enables the study of the functional effects of mutations recurrent in human tumors. See also: News and Views by Salahudeen & Kuo |
|
|
|
The ketone metabolite [beta]-hydroxybutyrate blocks NLRP3 inflammasome-mediated inflammatory disease pp263 - 269 Yun-Hee Youm, Kim Y Nguyen, Ryan W Grant, Emily L Goldberg, Monica Bodogai et al. doi:10.1038/nm.3804 Ketone bodies are elevated in response to fasting, a low-carbohydrate ketogenic diet or high-intensity exercise. Vishwa Deep Dixit and colleagues report that one metabolite, [beta]-hydroxybutyrate, inhibits the NLRP3 inflammasome. In vivo, [beta]-hydroxybutyrate is anti-inflammatory and suppresses NLRP3-mediated inflammatory disease. See also: News and Views by Levy et al. | Article by Coll et al. |
|
|
|
Functional correction in mouse models of muscular dystrophy using exon-skipping tricyclo-DNA oligomers pp270 - 275 Aurelie Goyenvalle, Graziella Griffith, Arran Babbs, Samir El Andaloussi, Kariem Ezzat et al. doi:10.1038/nm.3765 Use of a new generation anti-sense oligonucleotide to target exon skipping in multiple organ systems in two mouse models of muscular dystrophy |
|
|
|
A C-terminal HSP90 inhibitor restores glucocorticoid sensitivity and relieves a mouse allograft model of Cushing disease pp276 - 280 Mathias Riebold, Christian Kozany, Lee Freiburger, Michael Sattler, Michael Buchfelder et al. doi:10.1038/nm.3776 Inhibition of Hsp90 as its C-terminus allows for the mature folding of GR and its full activity, thus ameliorating Cushing symptoms in a mouse model. |
|
|
|
DNA methyltransferase 3a regulates osteoclast differentiation by coupling to an S-adenosylmethionine-producing metabolic pathway pp281 - 287 Keizo Nishikawa, Yoriko Iwamoto, Yasuhiro Kobayashi, Fumiki Katsuoka, Shin-ichi Kawaguchi et al. doi:10.1038/nm.3774 Proper bone structure is dependent on metabolism-mediated epigenetic regulation of osteoclast development. See also: News and Views by Ivashkiv |
|
Technical Report | Top |
|
|
|
Aptamer-functionalized lipid nanoparticles targeting osteoblasts as a novel RNA interference-based bone anabolic strategy pp288 - 294 Chao Liang, Baosheng Guo, Heng Wu, Ningsheng Shao, Defang Li et al. doi:10.1038/nm.3791 |
|
Top |
|
|
Advertisement |
|
Epigenome Roadmap Nature Publishing Group presents an online portal - the Epigenome Roadmap - which collects key research papers from The NIH Roadmap Epigenomics Program, complemented by thematical 'threads' to help the readers mine the wealth of available information. Access the Epigenome Roadmap for FREE at: nature.com/epigenomeroadmap Produced with exclusive support from Illumina | | | |
|
|
| | | | | | Natureevents is a fully searchable, multi-disciplinary database designed to maximise exposure for events organisers. The contents of the Natureevents Directory are now live. The digital version is available here. Find the latest scientific conferences, courses, meetings and symposia on natureevents.com. For event advertising opportunities across the Nature Publishing Group portfolio please contact natureevents@nature.com | | | | | | |
|
No comments:
Post a Comment